Canada - English - Health Canada

mylan pharmaceuticals ulc - cisplatin - solution - 1mg - cisplatin 1mg - antineoplastic agents

Canada - English - Health Canada

pfizer canada ulc - cisplatin - solution - 1mg - cisplatin 1mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections; sodium chloride - cisplatin injection is indicated for the palliative treatment of metastatic non-seminomatous germ cell carcinoma, advanced-stage refractory ovarian carcinoma, advanced-stage refractory bladder carcinoma and refractory squamous cell carcinoma of the head and neck. it may be used as a single agent or in combination with other chemotherapeutic agents. it may be employed, in appropriate circumstances, in addition to other modalities, eg radiotherapy or surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, solution - excipient ingredients: sodium chloride; mannitol; water for injections - cisplatin injection is indicated for the palliative treatment of metastatic non-seminomatous germ cell carcinoma, advanced-stage refractory ovarian carcinoma, advanced-stage refractory bladder carcinoma and refractory squamous cell carcinoma of the head and neck. it may be used as a single agent or in combination with other chemotherapeutic agents. it may be employed, in appropriate circumstances, in addition to other modalities, eg radiotherapy or surgery.

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml

United States - English - NLM (National Library of Medicine)

mylan institutional llc - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisplatin -

United States - English - NLM (National Library of Medicine)

corden pharma latina s.p.a. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - platinol-aq (cisplatin injection) is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of platinol-aq and cyclophosphamide. platinol-aq, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received platinol-aq therapy. platinol-aq is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. platinol-aq is contraindicated in patients with preexisting renal impairme

United States - English - NLM (National Library of Medicine)

corden pharma latina s.p.a. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - platinol (cisplatin for injection, usp) is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of platinol and cyclophosphamide. platinol, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received platinol therapy. platinol is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. platinol is contraindicated in patients with preexisting renal impairment. plati

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cisplatin 10 mg/10 ml - concentrate for solution for infusion - 1 mg/ml - cisplatin 1 mg/ml - cisplatin